证券代码：600267 证券简称：海正药业 公告编号：临2025-72号

Group 1 - The company, Zhejiang Haizheng Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Haizheng Nantong Co., Ltd., received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration [1] - The GMP inspection was conducted from October 31 to November 2, 2025, and concluded that the production lines and products met the required standards [1] - The inspection involved the production of Minocycline Hydrochloride, which is the first GMP compliance check for this product prior to its market launch [2] Group 2 - The production lines for Minocycline Hydrochloride have seen a total fixed asset investment of approximately 99.16 million yuan, with about 86.30 million yuan already completed [1] - Minocycline Hydrochloride is indicated for infections caused by various sensitive pathogens and was originally developed by Wyeth Pharmaceuticals [2] - In 2024, the global sales volume of Minocycline Hydrochloride was approximately 35,658.87 kg, with domestic sales accounting for about 7,914.50 kg [2]